Double-blind Comparative Study of SYR-472
NCT01632007
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
245
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes Mellitus
Interventions
DRUG:
SYR-472
DRUG:
Alogliptin 25 mg
DRUG:
Placebo
Sponsor
Takeda